Michael Ehlers, Biogen via Youtube
October 1, 2019 08:33 AM EDTUpdated 10:18 AM
R&D

Michael Ehlers jumps a list­ing ship, turn­ing to VC and star­tups as a dam­aged Bio­gen taps long­time vet Al San­drock to take his place

John Carroll

Editor & Founder

Al San­drock Bio­gen

Just a lit­tle more than 3 years af­ter Michael Ehlers took the lead job as glob­al head of R&D for the now deeply trou­bled Bio­gen, he’s jump­ing ship. And CEO Michel Vounatsos is nam­ing CMO Al San­drock, the ar­chi­tect of a deeply flawed pipeline strat­e­gy, as his re­place­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

A service from the Financial Times